Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13510864 | 0.82 | ALDH1A1 (0.34) | BRD4POLBSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL179780 | 0.77 | KMT2A (0.52) | BRD4POLBALDH1A1KMT2A | |
| SCHEMBL4509139 | 0.76 | — | — | |
| SCHEMBL10147187 | 0.75 | SMN1; SMN2 (0.53) | BRD4POLBSMN1; SMN2KCNH2 | |
| SCHEMBL28221636 | 0.75 | BRD4 (0.42) | BRD4POLBSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL18814685 | 0.75 | TLR8 (0.41) | POLBALDH1A1KMT2ATLR8TLR7 | |
| SCHEMBL15969910 | 0.73 | BRD4 (0.41) | BRD4POLBSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL21646212 | 0.73 | BRD4 (0.44) | BRD4POLBSMN1; SMN2ALDH1A1KMT2A | |
| Bromide SCHEMBL10795216 | 0.73 | TLR8 (0.50) | BRD4POLBADORA2ASMN1; SMN2CCNE1 | |
| SCHEMBL2638232 | 0.73 | KCNH2 (0.42) | BRD4POLBSMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011533-A1 | CARBOXYLIC ACID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海宇道生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220259198-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-114072390-A | RAD51 inhibitors | 赛泰尔治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247988-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200291014-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-9580392-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-28 | — | — | US | disclosed |
| US-9192577-B2 | Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20140343006-A1 | HIV Replication Inhibiting Pyrimidines | JANSSEN PHARMACEUTICA NV (NL) | 2014-11-20 | — | — | US | disclosed |
| US-8828982-B2 | Pyrimidine derivatives for the prevention of HIV infection | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-09-09 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN-CILAG (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343006-A1 | HIV Replication Inhibiting Pyrimidines | RRM2B, CCNO, RRM2 | BRD4 285/4885POLB 50/4885ADORA3 76/4885 |
| US-11247988-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | BRD4 1500/4885POLB 86/4885ADORA3 4657/4885 |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | BRD4 679/4885POLB 293/4885ADORA3 5/4885 |
| US-20220259198-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | BRD4 1500/4885POLB 86/4885ADORA3 4657/4885 |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | TYMS, PNP, DUT | BRD4 1067/4885POLB 18/4885ADORA3 226/4885 |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | NOX3, CBR3, CBR1 | BRD4 1466/4885POLB 1486/4885ADORA3 19/4885 |
| US-20200291014-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | BRD4 1500/4885POLB 86/4885ADORA3 4657/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | BRD4 1500/4885POLB 86/4885ADORA3 4657/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | BRD4 1500/4885POLB 86/4885ADORA3 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.